Barry E. Greene - 10 Nov 2022 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
President and CEO, Director
Signature
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Barry Greene
Issuer symbol
SAGE
Transactions as of
10 Nov 2022
Net transactions value
+$500,022
Form type
4
Filing time
15 Nov 2022, 15:04:20 UTC
Previous filing
15 Aug 2022
Next filing
15 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Purchase $500,022 +14,500 +45% $34.48 46,940 10 Nov 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $34.19 USD to $34.86 USD. The price reported above reflects the weighted average purchase price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.